Literature DB >> 34507356

Optimizing outcomes in primary mediastinal B-cell lymphoma: is R-CHOP enough?

Michael R Cook1, Kieron Dunleavy1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34507356      PMCID: PMC8679670          DOI: 10.1182/bloodadvances.2021005190

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


× No keyword cloud information.
  22 in total

1.  Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study.

Authors:  Anthony J Swerdlow; Rosie Cooke; Andrew Bates; David Cunningham; Stephen J Falk; Dianne Gilson; Barry W Hancock; Sarah J Harris; Alan Horwich; Peter J Hoskin; David C Linch; T Andrew Lister; Helen H Lucraft; John A Radford; Andrea M Stevens; Isabel Syndikus; Michael V Williams
Journal:  J Clin Oncol       Date:  2012-06-25       Impact factor: 44.544

2.  Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R.

Authors:  Lisa Giulino-Roth; Tara O'Donohue; Zhengming Chen; Nancy L Bartlett; Ann LaCasce; William Martin-Doyle; Matthew J Barth; Kimberly Davies; Kristie A Blum; Beth Christian; Carla Casulo; Sonali M Smith; James Godfrey; Amanda Termuhlen; Matthew J Oberley; Sarah Alexander; Sheila Weitzman; Burton Appel; Benjamin Mizukawa; Jakub Svoboda; Zeinab Afify; Melinda Pauly; Hema Dave; Rebecca Gardner; Deborah M Stephens; William A Zeitler; Christopher Forlenza; Jennifer Levine; Michael E Williams; Jody L Sima; Catherine M Bollard; John P Leonard
Journal:  Br J Haematol       Date:  2017-10-29       Impact factor: 6.998

Review 3.  Emerging biological insights and novel treatment strategies in primary mediastinal large B-cell lymphoma.

Authors:  Kieron Dunleavy; Christian Steidl
Journal:  Semin Hematol       Date:  2015-01-17       Impact factor: 3.851

4.  Poor predictive value of positive interim FDG-PET/CT in primary mediastinal large B-cell lymphoma.

Authors:  Julien Lazarovici; Marie Terroir; Julia Arfi-Rouche; Jean-Marie Michot; Sacha Mussot; Valentina Florea; Maria-Rosa Ghigna; Peggy Dartigues; Cynthia Petrovanu; Alina Danu; Christophe Fermé; Vincent Ribrag; David Ghez
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-21       Impact factor: 9.236

5.  Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade.

Authors:  Bjoern Chapuy; Chip Stewart; Andrew J Dunford; Jaegil Kim; Kirsty Wienand; Atanas Kamburov; Gabriel K Griffin; Pei-Hsuan Chen; Ana Lako; Robert A Redd; Claire M Cote; Matthew D Ducar; Aaron R Thorner; Scott J Rodig; Gad Getz; Margaret A Shipp
Journal:  Blood       Date:  2019-12-26       Impact factor: 22.113

6.  Characterization of DLBCL with a PMBL gene expression signature.

Authors:  Gerben Duns; Elena Viganò; Daisuke Ennishi; Clementine Sarkozy; Stacy S Hung; Elizabeth Chavez; Katsuyoshi Takata; Christopher Rushton; Aixiang Jiang; Susana Ben-Neriah; Bruce W Woolcock; Graham W Slack; Eric D Hsi; Jeffrey W Craig; Laura K Hilton; Sohrab P Shah; Pedro Farinha; Anja Mottok; Randy D Gascoyne; Ryan D Morin; Kerry J Savage; David W Scott; Christian Steidl
Journal:  Blood       Date:  2021-07-15       Impact factor: 22.113

7.  Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.

Authors:  Gilles Salles; Johannes Duell; Eva González Barca; Olivier Tournilhac; Wojciech Jurczak; Anna Marina Liberati; Zsolt Nagy; Aleš Obr; Gianluca Gaidano; Marc André; Nagesh Kalakonda; Martin Dreyling; Johannes Weirather; Maren Dirnberger-Hertweck; Sumeet Ambarkhane; Günter Fingerle-Rowson; Kami Maddocks
Journal:  Lancet Oncol       Date:  2020-06-05       Impact factor: 41.316

8.  Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.

Authors:  Kieron Dunleavy; Stefania Pittaluga; Lauren S Maeda; Ranjana Advani; Clara C Chen; Julie Hessler; Seth M Steinberg; Cliona Grant; George Wright; Gaurav Varma; Louis M Staudt; Elaine S Jaffe; Wyndham H Wilson
Journal:  N Engl J Med       Date:  2013-04-11       Impact factor: 91.245

9.  Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.

Authors:  Philippe Armand; Scott Rodig; Vladimir Melnichenko; Catherine Thieblemont; Kamal Bouabdallah; Gayane Tumyan; Muhit Özcan; Sergio Portino; Laura Fogliatto; Maria D Caballero; Jan Walewski; Zafer Gulbas; Vincent Ribrag; Beth Christian; Guilherme Fleury Perini; Gilles Salles; Jakub Svoboda; Jasmine Zain; Sanjay Patel; Pei-Hsuan Chen; Azra H Ligon; Jing Ouyang; Donna Neuberg; Robert Redd; Arkendu Chatterjee; Arun Balakumaran; Robert Orlowski; Margaret Shipp; Pier Luigi Zinzani
Journal:  J Clin Oncol       Date:  2019-10-14       Impact factor: 44.544

10.  End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making.

Authors:  Christopher Melani; Ranjana Advani; Mark Roschewski; Kelsey M Walters; Clara C Chen; Lucia Baratto; Mark A Ahlman; Milos D Miljkovic; Seth M Steinberg; Jessica Lam; Margaret Shovlin; Kieron Dunleavy; Stefania Pittaluga; Elaine S Jaffe; Wyndham H Wilson
Journal:  Haematologica       Date:  2018-05-10       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.